D
Recursion Pharmaceuticals, Inc. RXRX
$6.35 $0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

12/31/2024 09/30/2024 06/30/2024 03/31/2024 12/31/2023
Net Income -92.38% -3.04% -27.13% -39.87% -61.75%
Total Depreciation and Amortization 71.47% -5.01% 61.79% 97.88% 135.00%
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items 96.49% 57.55% 20.09% 43.04% 123.43%
Change in Net Operating Assets 153.66% 159.75% -1.41% -49.36% -1,775.21%
Cash from Operations -55.82% 18.78% -21.87% -39.53% -65.54%
Capital Expenditure 37.20% -512.35% 70.21% -28.56% 74.09%
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions 390,387.32% -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities 0.00% -100.00% -- -- --
Cash from Investing 11,171.38% -1,214.70% -103.70% -24.59% 68.82%
Total Debt Issued -- -- -- -- --
Total Debt Repaid -202.74% -9,429.17% -8.33% -8.33% -2,917.39%
Issuance of Common Stock -84.34% -65.14% 6,804.96% 615.47% -44.76%
Repurchase of Common Stock -- -- -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities -- -- -- -- --
Cash from Financing -86.81% -69.38% 6,848.03% 623.05% -45.23%
Foreign Exchange rate Adjustments -2,900.00% 450.43% -165.19% -10,850.00% 140.39%
Miscellaneous Cash Flow Adjustments -- -- -- -- --
Net Change in Cash 3,863.80% -139.19% 369.41% -24.16% -95.52%
Weiss Ratings